Idronoxil
- Generic Name
- Idronoxil
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H12O3
- CAS Number
- 81267-65-4
- Unique Ingredient Identifier
- 995FT1W541
- Background
Idronoxil is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called signal transduction inhibitors.
- Indication
Intended for the treatment of various forms of cancer.
- Associated Conditions
- -
- Associated Therapies
- -
A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2010-04-08
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00557037
- Locations
- 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-10-02
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 142
- Registration Number
- NCT00382811
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸Associates in Women's Health, Wichita, Kansas, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Yale University
- Target Recruit Count
- 31
- Registration Number
- NCT00303888
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-09-09
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT00091377
- Locations
- 🇦🇺
Royal Women's Hospital, Carlton, Victoria, Australia
🇺🇸Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States
Phenoxodiol in Treating Patients With Refractory Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Kazia Therapeutics Limited
- Target Recruit Count
- 36
- Registration Number
- NCT00022295
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.